This study is looking for healthy volunteers, aged 18 to 50, to test a new drug called AZD1613. The main goal is to understand if AZD1613 is safe and how well your body tolerates it. Researchers will also study how the drug moves through your body (pharmacokinetics), what effects it has on your body (pharmacodynamics), and if your immune system reacts to it (immunogenicity). You would receive either AZD1613 or a placebo (an inactive substance) as an injection under the skin or into a vein. The study is currently unclear on its recruitment status.

Study design

This is a randomized, single-blind, placebo-controlled study with up to 136 healthy participants. It has two parts: Part A for a single dose and Part B for multiple doses.

What's involved

You would have a screening period of up to 28 days, receive the study drug or placebo on specific days, and then have follow-up visits for up to 161 days.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for adverse events for up to 161 days after the first dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.